Skip to main content

Table 6 Categorization of irAEs

From: Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?

irAEs

No. (%)

Median days to onset

Grade of irAEs, n, 1/2/3/4 (%)

Total

29 (100)

70

20 (68.97)/8 (27.59)/1 (3.44)/0

Hypothyroidism

6 (20.69)

94

5 (83.33)/1 (16.67)/0/0

Hyperthyroidism

5 (17.24)

92

2 (0.40)/3 (0.60)/0/0

Diarrhea/colitis

3 (10.34)

48

2 (66.67)/0/1 (33.33)/0

Rash

3 (10.34)

70

3 (100)/0/0/0

Myocardial enzyme increased

3 (10.34)

21

1 (33.33)/2 (66.67)/0/0

AST/ALT/Bilirubin increased

2 (6.90)

38.5

1 (50)/1 (50)/0/0

Creatinine increased

2 (6.90)

148.5

1 (50)/1 (50)/0/0

Myalgia

1 (3.45)

71

1 (100)/0/0/0

Pruritus

1 (3.45)

26

1 (100)/0/0/0

Thrombocytopenia

1 (3.45)

27

1 (100)/0/0/0

Hypohemoglobin

1 (3.45)

28

1 (100)/0/0/0

Fatigue

1 (3.45)

106

1 (100)/0/0/0